London, UK – 17th November 2026 – Curaleaf Laboratories, a UK manufacturer of cannabis-based medicinal products, today announced a partnership with PURPLEFARM to manufacture, package and distribute PURPLEFARM products across the United Kingdom.

The partnership brings together Curaleaf Laboratories’ established EU-GMP pharmaceutical manufacturing capabilities and nationwide distribution network with PURPLEFARM’s commitment to producing accessible medical cannabis products. Together, the companies aim to expand access to cannabis-based medicines for healthcare professionals and eligible patients across the UK while maintaining the standards of quality, safety and regulatory compliance.

Under the agreement, Curaleaf Laboratories will manufacture and distribute PURPLEFARM products for the UK market, leveraging its MHRA-compliant facilities and expertise in pharmaceutical-grade production. The collaboration is designed to ensure a reliable supply of EU-GMP products while supporting the continued growth of the UK’s medical cannabis sector.

Richard Hodgson, Managing Director at Curaleaf Laboratories commented: “This partnership reflects our commitment to working with leading international partners to broaden eligible patients’ access to cannabis-based medicines. PURPLEFARM shares our focus on quality, consistency and patient outcomes, making them an ideal partner as we continue to strengthen the range of products available to healthcare professionals and eligible patients throughout the UK.”

Mitchell Alswiti, CEO & Co-Founder at PURPLEFARM added: “Partnering with Curaleaf Laboratories represents an important milestone in our international growth strategy. Their expertise in pharmaceutical manufacturing, regulatory excellence and UK distribution makes them the natural partner to expand access to PURPLEFARM products to the UK market. Together, we look forward to delivering EU-GMP products to patients who may benefit from cannabis-based medicines.”

The partnership further reinforces both organisations’ commitment to supporting healthcare professionals and improving patient access through reliable manufacturing, robust quality assurance and efficient distribution.

PURPLEFARM products are now available in the UK through authorised prescribing pathways and meet all applicable regulatory requirements.

Healthcare professionals seeking information on prescribing or ordering can contact Curaleaf Laboratories here or [email protected].

Disclaimer: This press release includes information about cannabis-based products for medicinal use. These products are available in the UK only via prescription from a specialist doctor. This announcement is not intended to promote prescription-only medicines to the public. Treatment decisions should be made by a qualified healthcare professional.

About Curaleaf Laboratories

Curaleaf Laboratories is one of the UK-leading experts in the manufacturing and distribution of EU-GMP medical cannabis. With an MHRA-approved medical cannabis manufacturing facility and a comprehensive quality management system, Curaleaf Laboratories is meeting the growing needs of healthcare professionals and patients for a consistent range of medical cannabis manufactured to EU-GMP standards, with varying novel dosage forms and levels of cannabinoid content. Curaleaf Laboratories was the first manufacturer of full spectrum medical cannabis in the UK.

Part of Curaleaf International since 2019, Curaleaf Laboratories has evolved from an established specials medicines manufacturer with over a decade of expertise in unlicensed medicines. With that experience, Curaleaf Laboratories is widening access to prescribers, clinics and pharmacies across the UK, with a focus on innovation and collaboration, while operating as a manufacturer, distributor and partner for licensed producers and cultivators.

About PURPLEFARM

PURPLEFARM is a Canadian cannabis producer specializing in premium indoor cultivation, genetic selection and quality-focused production. With cultivation facilities in Ontario and New Brunswick, the company combines carefully selected genetics with controlled cultivation and post-harvest practices to deliver consistent, high-quality cannabis. Through partnerships with established pharmaceutical and distribution organizations, PURPLEFARM continues to expand its presence in regulated international medical cannabis markets.

Leave a Reply

News

More insights

View all news